Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStandard BioTools reports Q1 2026 results, updates full-year revenue outlook
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Company disclosed first quarter 2026 financial results through press release. Specific revenue, earnings, and other metrics are in the attached exhibit, not the 8-K body itself.
Item 2.02 verify on EDGAR → -
high
Management provided updated full-year 2026 revenue guidance. This forward-looking outlook was furnished but not filed, limiting legal liability for projections.
Item 7.01 verify on EDGAR → -
medium
The 8-K references financial information by incorporation only. Investors must review the press release exhibit (99.1) for actual quarterly numbers and guidance details.
8-K: Financial Results verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade LAB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify